U.S. Markets closed

Aratana Therapeutics, Inc. (PETX)


NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
7.00+0.02 (+0.29%)
At close: 4:00PM EDT
People also watch
OMEROMEDOCULPTCTPTLA

Aratana Therapeutics, Inc.

11400 Tomahawk Creek Parkway
Suite 340
Leawood, KS 66211
United States
913-353-1000
http://www.aratana.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees84

Key Executives

NameTitlePayExercisedAge
Dr. Steven St. Peter M.D.Co-Founder, Chief Exec. Officer, Pres & Director697.8kN/A51
Mr. Craig A. Tooman MBACFO & Treasurer475.4kN/A51
Mr. Brent A. StandridgeChief Operating Officer339.4kN/A59
Dr. Ernst Heinen D.V.M., Ph.D.Chief Devel. Officer402.3kN/A54
Mr. John C. AyresGen. Counsel & Sec.N/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Aratana Therapeutics, Inc., a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics. The company markets GALLIPRANT for the control of pain and inflammation associated with osteoarthritis in dogs; ENTYCE for appetite stimulation in dogs; and NOCITA, a post-operative anesthetic for cranial cruciate ligament surgery in dogs. The company is also developing AT-002 for evaluating capromorelin for weight management in cats with chronic kidney disease; AT-003, a bupivacaine liposome injectable suspension for post-operative pain management in cats; AT-006, an anti-viral for the treatment of feline herpes virus-induced ophthalmic conditions for cats; AT-016, an adipose-derived allogeneic stem cell therapeutic candidate for the treatment of osteoarthritis pain in dogs; and AT-018, an oral CRTH2 antagonist for the potential treatment of atopic dermatitis in dogs. In addition, the company’s licensed products include BLONTRESS, a canonized monoclonal antibody for the treatment of B-cell lymphoma in dogs; and TACTRESS, a canonized monoclonal antibody for the treatment of T-cell lymphoma in dogs, as well as AT-014, a novel her2/neu-directed cancer immunotherapy for the treatment of canine osteosarcoma for dogs. It has collaboration agreement with Elanco Animal Health, Inc. to develop, manufacture, and commercialize GRAPIPRANT products. Aratana Therapeutics, Inc. was founded in 2010 and is headquartered in Leawood, Kansas.

Corporate Governance

Aratana Therapeutics, Inc.’s ISS Governance QualityScore as of June 2, 2017 is 10. The pillar scores are Audit: 10; Board: 3; Shareholder Rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.